• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

With approval in sight, Vifor expands deal for partner's anti-itch drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 20, 2020 at 10:13: PM
via Cara Therapeutics struck a licensing deal with Vifor Pharma that may be worth as much as $440 million as the biotech prepares to seek approval of its anti-itch medicine for dialysis patients with chronic kidney disease-associated pruritus (CKD-aP).

article source
 

<



Similar threads

cafead
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Replies
0
Views
178
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Approval in sight, Perceptive, OrbiMed double down on Foamix&#039;s antibiotic foam to the...
Replies
0
Views
492
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Replies
0
Views
1
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Apple Watch sleep apnea detection gets FDA approval
Replies
0
Views
18
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote